candesartan has been researched along with omapatrilat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Idikio, H; Jugdutt, BI; Palaniyappan, A; Uwiera, RR | 1 |
| Idikio, H; Jugdutt, BI; Jugdutt, C; Menon, V; Palaniyappan, A; Uwiera, RR | 1 |
2 other study(ies) available for candesartan and omapatrilat
| Article | Year |
|---|---|
Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cardiovascular Agents; Cytokines; Extracellular Matrix; Humans; Isoenzymes; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardial Reperfusion; Myocardium; Nitric Oxide Synthase; Peroxidase; Protease Inhibitors; Pyridines; Random Allocation; Rats; Tetrazoles; Thiazepines; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-3; Ventricular Remodeling | 2009 |
Attenuation of increased secretory leukocyte protease inhibitor, matricellular proteins and angiotensin II and left ventricular remodeling by candesartan and omapatrilat during healing after reperfused myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Collagen; Male; Myocardial Infarction; Myocardial Reperfusion; Osteonectin; Pyridines; Rats, Sprague-Dawley; Secretory Leukocyte Peptidase Inhibitor; Tetrazoles; Thiazepines; Ventricular Remodeling | 2013 |